Pressure effects on the structural and superconducting transitions in La₃Co₄Sn₁₃

La3Co4Sn13 is a superconducting material with transition temperature at Tc = 2.70 K, which presents a superlattice structural transition at T ∗ ≃ 150 K, a common feature for this class of compounds. However, for this material, it is not clear that at T ∗ the lattice distortions arise from a charge density wave (CDW) or from a distinct microscopic origin. Interestingly, it has been suggested in isostructural non-magnetic intermetallic compounds that T ∗ can be suppressed to zero temperature, by combining chemical and external pressure, and a quantum critical point is argued to be observed near these critical doping/pressure. Our study shows that application of pressure on single-crystalline La3Co4Sn13 enhances Tc and decreases T ∗ . We observe thermal hysteresis loops for cooling/heating cycles around T ∗ for P & 0.6 GPa, in electrical resistivity measurements, which are not seen in x-ray diffraction data. The hysteresis in electrical measurements may be due to the pinning of the CDW phase to impurities/defects, while the superlattice structural transition maintains its ambient pressure second-order transition nature under pressure. From our experiments we estimate that T ∗ vanishes at around 5.5 GPa, though no quantum critical behavior is observed up to 2.53 GPa

PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS

Background: The rarity of mutations in PALB2, CHEK2 and ATM make it difficult to estimate precisely associated cancer risks. Population-based family studies have provided evidence that at least some of these mutations are associated with breast cancer risk as high as those associated with rare BRCA2 mutations. We aimed to estimate the relative risks associated with specific rare variants in PALB2, CHEK2 and ATM via a multicentre case-control study.Methods: We genotyped 10 rare mutations using the custom iCOGS array: PALB2 c.1592delT, c.2816T&gt;G and c.3113G&gt;A, CHEK2c.349A&gt;G, c.538C&gt;T, c.715G&gt;A, c.1036C&gt;T, c.1312G&gt;T, and c.1343T&gt;G and ATM c.7271T&gt;G. We assessed associations with breast cancer risk (42 671 cases and 42 164 controls), as well as prostate (22 301 cases and 22 320 controls) and ovarian (14 542 cases and 23 491 controls) cancer risk, for each variant.Results: For European women, strong evidence of association with breast cancer risk was observed for PALB2 c.1592delT OR 3.44 (95% CI 1.39 to 8.52, p=7.1×10−5), PALB2 c.3113G&gt;A OR 4.21 (95% CI 1.84 to 9.60, p=6.9×10−8) and ATM c.7271T&gt;G OR 11.0 (95% CI 1.42 to 85.7, p=0.0012). We also found evidence of association with breast cancer risk for three variants in CHEK2, c.349A&gt;G OR 2.26 (95% CI 1.29 to 3.95), c.1036C&gt;T OR 5.06 (95% CI 1.09 to 23.5) and c.538C&gt;T OR 1.33 (95% CI 1.05 to 1.67) (p≤0.017). Evidence for prostate cancer risk was observed for CHEK2 c.1343T&gt;G OR 3.03 (95% CI 1.53 to 6.03, p=0.0006) for African men and CHEK2 c.1312G&gt;T OR 2.21 (95% CI 1.06 to 4.63, p=0.030) for European men. No evidence of association with ovarian cancer was found for any of these variants.Conclusions: This report adds to accumulating evidence that at least some variants in these genes are associated with an increased risk of breast cancer that is clinically important.</p

A922 Sequential measurement of 1 hour creatinine clearance (1-CRCL) in critically ill patients at risk of acute kidney injury (AKI)

Meeting abstrac